Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population

Sylvia H. Ley, Stewart B. Harris, Philip W. Connelly, Mary Mamakeesick, Joel Gittelsohn, Thomas M. Wolever, Robert A. Hegele, Bernard Zinman, Anthony J. Hanley

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Expanding evidence indicates that apolipoprotein B (apo B) is superior to LDL cholesterol as a marker of vascular disease. Although traditional lipid measures are known to predict type 2 diabetes, limited data are available regarding apo B. We assessed the association of apo B with incident type 2 diabetes and compared it with traditional lipid variables as a risk predictor in aboriginal Canadians. METHODS: Of an initial cohort of 606 individuals without diabetes in 1993-1995, 540 were contacted for the 10-year follow-up evaluation in 2003-2005. Fasting and 2-h postload glucose concentrations were obtained at baseline and follow-up to determine incident type 2 diabetes. Baseline fasting serum lipids were measured with standard laboratory procedures. RESULTS: The cumulative 10-year incidence of type 2 diabetes was 17.5%. High concentrations of apo B, triglycerides, triglycerides, and LDL cholesterol, and low concentrations of HDL cholesterol were individually associated with incident type 2 diabetes in univariate analyses. Comparing C statistics of univariate models showed apo B to be a superior determinant of incident diabetes compared with LDL (P = 0.026) or HDL (P = 0.004) cholesterol. With multivariate adjustment including waist circumference, apo B (odds ratio, 1.50; 95% CI, 1.11-2.02) and triglycerides (odds ratio, 1.49; 95% CI, 1.12-1.98) remained associated with incident diabetes, whereas LDL and HDL cholesterol became nonsignificant. CONCLUSIONS: The association of plasma apo B with incident type 2 diabetes and its better prediction of risk compared with LDL or HDL cholesterol suggest the potential for the use of apo B in type 2 diabetes risk communication and prevention.

Original languageEnglish (US)
Pages (from-to)666-670
Number of pages5
JournalClinical Chemistry
Volume56
Issue number4
DOIs
StatePublished - Apr 1 2010

Fingerprint

Apolipoproteins B
Medical problems
Type 2 Diabetes Mellitus
LDL Cholesterol
Population
HDL Cholesterol
Triglycerides
Lipids
Fasting
Odds Ratio
Social Adjustment
Waist Circumference
Vascular Diseases
Communication
Cholesterol
Glucose
Statistics
Incidence
Plasmas
Serum

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Ley, S. H., Harris, S. B., Connelly, P. W., Mamakeesick, M., Gittelsohn, J., Wolever, T. M., ... Hanley, A. J. (2010). Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population. Clinical Chemistry, 56(4), 666-670. https://doi.org/10.1373/clinchem.2009.136994

Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population. / Ley, Sylvia H.; Harris, Stewart B.; Connelly, Philip W.; Mamakeesick, Mary; Gittelsohn, Joel; Wolever, Thomas M.; Hegele, Robert A.; Zinman, Bernard; Hanley, Anthony J.

In: Clinical Chemistry, Vol. 56, No. 4, 01.04.2010, p. 666-670.

Research output: Contribution to journalArticle

Ley, SH, Harris, SB, Connelly, PW, Mamakeesick, M, Gittelsohn, J, Wolever, TM, Hegele, RA, Zinman, B & Hanley, AJ 2010, 'Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population', Clinical Chemistry, vol. 56, no. 4, pp. 666-670. https://doi.org/10.1373/clinchem.2009.136994
Ley, Sylvia H. ; Harris, Stewart B. ; Connelly, Philip W. ; Mamakeesick, Mary ; Gittelsohn, Joel ; Wolever, Thomas M. ; Hegele, Robert A. ; Zinman, Bernard ; Hanley, Anthony J. / Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population. In: Clinical Chemistry. 2010 ; Vol. 56, No. 4. pp. 666-670.
@article{32f675064e5549829ad8548d200a06d0,
title = "Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population",
abstract = "BACKGROUND: Expanding evidence indicates that apolipoprotein B (apo B) is superior to LDL cholesterol as a marker of vascular disease. Although traditional lipid measures are known to predict type 2 diabetes, limited data are available regarding apo B. We assessed the association of apo B with incident type 2 diabetes and compared it with traditional lipid variables as a risk predictor in aboriginal Canadians. METHODS: Of an initial cohort of 606 individuals without diabetes in 1993-1995, 540 were contacted for the 10-year follow-up evaluation in 2003-2005. Fasting and 2-h postload glucose concentrations were obtained at baseline and follow-up to determine incident type 2 diabetes. Baseline fasting serum lipids were measured with standard laboratory procedures. RESULTS: The cumulative 10-year incidence of type 2 diabetes was 17.5{\%}. High concentrations of apo B, triglycerides, triglycerides, and LDL cholesterol, and low concentrations of HDL cholesterol were individually associated with incident type 2 diabetes in univariate analyses. Comparing C statistics of univariate models showed apo B to be a superior determinant of incident diabetes compared with LDL (P = 0.026) or HDL (P = 0.004) cholesterol. With multivariate adjustment including waist circumference, apo B (odds ratio, 1.50; 95{\%} CI, 1.11-2.02) and triglycerides (odds ratio, 1.49; 95{\%} CI, 1.12-1.98) remained associated with incident diabetes, whereas LDL and HDL cholesterol became nonsignificant. CONCLUSIONS: The association of plasma apo B with incident type 2 diabetes and its better prediction of risk compared with LDL or HDL cholesterol suggest the potential for the use of apo B in type 2 diabetes risk communication and prevention.",
author = "Ley, {Sylvia H.} and Harris, {Stewart B.} and Connelly, {Philip W.} and Mary Mamakeesick and Joel Gittelsohn and Wolever, {Thomas M.} and Hegele, {Robert A.} and Bernard Zinman and Hanley, {Anthony J.}",
year = "2010",
month = "4",
day = "1",
doi = "10.1373/clinchem.2009.136994",
language = "English (US)",
volume = "56",
pages = "666--670",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "4",

}

TY - JOUR

T1 - Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population

AU - Ley, Sylvia H.

AU - Harris, Stewart B.

AU - Connelly, Philip W.

AU - Mamakeesick, Mary

AU - Gittelsohn, Joel

AU - Wolever, Thomas M.

AU - Hegele, Robert A.

AU - Zinman, Bernard

AU - Hanley, Anthony J.

PY - 2010/4/1

Y1 - 2010/4/1

N2 - BACKGROUND: Expanding evidence indicates that apolipoprotein B (apo B) is superior to LDL cholesterol as a marker of vascular disease. Although traditional lipid measures are known to predict type 2 diabetes, limited data are available regarding apo B. We assessed the association of apo B with incident type 2 diabetes and compared it with traditional lipid variables as a risk predictor in aboriginal Canadians. METHODS: Of an initial cohort of 606 individuals without diabetes in 1993-1995, 540 were contacted for the 10-year follow-up evaluation in 2003-2005. Fasting and 2-h postload glucose concentrations were obtained at baseline and follow-up to determine incident type 2 diabetes. Baseline fasting serum lipids were measured with standard laboratory procedures. RESULTS: The cumulative 10-year incidence of type 2 diabetes was 17.5%. High concentrations of apo B, triglycerides, triglycerides, and LDL cholesterol, and low concentrations of HDL cholesterol were individually associated with incident type 2 diabetes in univariate analyses. Comparing C statistics of univariate models showed apo B to be a superior determinant of incident diabetes compared with LDL (P = 0.026) or HDL (P = 0.004) cholesterol. With multivariate adjustment including waist circumference, apo B (odds ratio, 1.50; 95% CI, 1.11-2.02) and triglycerides (odds ratio, 1.49; 95% CI, 1.12-1.98) remained associated with incident diabetes, whereas LDL and HDL cholesterol became nonsignificant. CONCLUSIONS: The association of plasma apo B with incident type 2 diabetes and its better prediction of risk compared with LDL or HDL cholesterol suggest the potential for the use of apo B in type 2 diabetes risk communication and prevention.

AB - BACKGROUND: Expanding evidence indicates that apolipoprotein B (apo B) is superior to LDL cholesterol as a marker of vascular disease. Although traditional lipid measures are known to predict type 2 diabetes, limited data are available regarding apo B. We assessed the association of apo B with incident type 2 diabetes and compared it with traditional lipid variables as a risk predictor in aboriginal Canadians. METHODS: Of an initial cohort of 606 individuals without diabetes in 1993-1995, 540 were contacted for the 10-year follow-up evaluation in 2003-2005. Fasting and 2-h postload glucose concentrations were obtained at baseline and follow-up to determine incident type 2 diabetes. Baseline fasting serum lipids were measured with standard laboratory procedures. RESULTS: The cumulative 10-year incidence of type 2 diabetes was 17.5%. High concentrations of apo B, triglycerides, triglycerides, and LDL cholesterol, and low concentrations of HDL cholesterol were individually associated with incident type 2 diabetes in univariate analyses. Comparing C statistics of univariate models showed apo B to be a superior determinant of incident diabetes compared with LDL (P = 0.026) or HDL (P = 0.004) cholesterol. With multivariate adjustment including waist circumference, apo B (odds ratio, 1.50; 95% CI, 1.11-2.02) and triglycerides (odds ratio, 1.49; 95% CI, 1.12-1.98) remained associated with incident diabetes, whereas LDL and HDL cholesterol became nonsignificant. CONCLUSIONS: The association of plasma apo B with incident type 2 diabetes and its better prediction of risk compared with LDL or HDL cholesterol suggest the potential for the use of apo B in type 2 diabetes risk communication and prevention.

UR - http://www.scopus.com/inward/record.url?scp=77950561416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950561416&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2009.136994

DO - 10.1373/clinchem.2009.136994

M3 - Article

C2 - 20110448

AN - SCOPUS:77950561416

VL - 56

SP - 666

EP - 670

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 4

ER -